Impact of virus testing on COVID-19 case fatality rate: estimate using a fixed-effects model

Anthony Terriau, Arthur Poirier, Julien Albertini, Quentin Le Bastard

► To cite this version:

Anthony Terriau, Arthur Poirier, Julien Albertini, Quentin Le Bastard. Impact of virus testing on COVID-19 case fatality rate: estimate using a fixed-effects model. 2020. halshs-02559354

HAL Id: halshs-02559354

<https://shs.hal.science/halshs-02559354>

Preprint submitted on 30 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

WP 2015 – April 2020

Impact of virus testing on COVID-19 case fatality rate: estimate using a fixed-effects model

Anthony Terriau, Arthur Poirier, Julien Albertini, Quentin Le Bastard

Abstract:

In response to the coronavirus disease (COVID-19) pandemic, governments have adopted a variety of public health measures. In this study, we aimed to evaluate the impact of testing on the fatality rate. We use data on inpatients across French geographic areas and propose a novel methodology that exploits policy discontinuities at region borders to estimate the effect of testing symptomatic individuals on the case-fatality rate in France. Our identification strategy is based on the fact that, in France, testing policies are determined regionally by the Regional Public Health Agencies. We compare all contiguous department pairs located on the opposite sides of a region border. Department pairs have different testing rates but share similar health trends. The heterogeneity in testing rate between department pairs together with the similarities in other dimensions allow us to mimic the existence of treatment and control groups and to identify the impact of testing on the mortality rate. We find that in France, the increase of one percentage point in the test rate is associated with a decrease of 0.001 percentage point in the death rate. Putting this number into perspective involves that for each additional 1000 tests, one person would have remained alive.

Keywords:

Search and matching, Layoffs, Recalls, Experience rating, Unemployment insurance

JEL codes:

E23, E32, J63, J64, J65

Impact of virus testing on COVID-19 case fatality rate: estimate using a fixed-effects model

Anthony Terriau* Arthur Poirier[†] Julien Albertini[‡]
Quentin Le Bastard[§]

April 29, 2020

Abstract

In response to the coronavirus disease (COVID-19) pandemic, governments have adopted a variety of public health measures. In this study, we aimed to evaluate the impact of testing on the fatality rate. We use data on inpatients across French geographic areas and propose a novel methodology that exploits policy discontinuities at region borders to estimate the effect of testing symptomatic individuals on the case-fatality rate in France. Our identification strategy is based on the fact that, in France, testing policies are determined regionally by the Regional Public Health Agencies. We compare all contiguous department pairs located on the opposite sides of a region border. Department pairs have different testing rates but share similar health trends. The heterogeneity in testing rate between department pairs together with the similarities in other dimensions allow us to mimic the existence of treatment and control groups and to identify the impact of testing on the mortality rate. We find that in France, the increase of one percentage point in the test rate is associated with a decrease of 0.001 percentage point in the death rate. Putting this number into perspective involves that for each additional 1000 tests, one person would have remained alive.

*GAINS, Le Mans University

[†]GAINS, Le Mans University

[‡]Univ Lyon, Université Lumière Lyon 2, GATE UMR 5824, F-69130 Ecully, France; e-mail: julien.albertini@univ-lyon2.fr

[§]MiHAR, University of Nantes

Research in context

Evidence before to this study.

Since the beginning of the COVID-19 pandemic, countries have implemented different strategic plans to limit the disease outbreak. Testing population is an important instrument, not only to prevent the spreading of the disease by mean of quarantining but also to improve general management of the infected patients. Knowing how much of the heterogeneity in the case-fatality rate is accounted for by testing strategies is then of great interest. We conducted a search on PubMed and Google Scholar on April 21, 2020 for articles using the terms (COVID-19 OR SARS-CoV-2 OR 2019-nCoV) AND (testing OR RT-PCR). We found no studies estimating the impact of testing for the COVID-19 prevalence on the fatality rate.

Added value of this study

To our knowledge, we are the firsts to estimate the impact of testing policies on the COVID-19 fatality rate. We have developed an original methodology that uses cross-sectional differences along French departments and the testing policy discontinuities at region borders. Beyond the estimation results, we consider that our methodology is well-suited for this type of evaluation and could be extrapolated for further countries or epidemiological situations. Our findings may also serve as calibration targets for the parameters of SIR epidemiology models investigating screening policies.

Implications of all the available evidence

Being able to know how testing policies diminish COVID-19 fatality rate is a major concern among policymakers. Providing such estimation could help governments designing better strategies to fight the current pandemic and avoid a potential second wave.

Introduction

Since it was reported in late December 2019 from Hubei province in China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has now spread worldwide with more than 2 million confirmed cases by the end of April 2020.¹ The outbreak reached Europe via Italy at the end of February and quickly affected the entire continent, making Europe the epicenter by mid-March. The World Health Organization (WHO) declared the SARS-CoV2 to be a pandemic in mid-March 2020. While research is still underway to find a curative treatment, the increasing number of severe cases admitted to hospital has raised fears of overburdening the health care systems.

To prevent such a situation, governments have implemented various public health measures such as mobility restrictions, social distancing, or mass screening strategies. On March 16th, the head of the WHO pronounced in favor of massive population tests, because “you cannot fight a fire blindfolded”.² Yet, there is a growing debate about the impact of mass testing on mortality rates.³ We have observed strong differences in testing rates between countries; for example, South-Korea, Germany or Iceland, have undertaken important screening policies and now report low case-fatality rates. On the contrary, countries like Spain or France have restricted access to diagnostic tests for in-patients or health care workers and now report higher mortality rates.⁴ Unfortunately, cross-country comparisons are difficult due to the strong heterogeneity among countries. Even in the United States of America, endowments for medical centers and lockdown strategies are very different from one state to another.

By contrast, France kept a relatively centralized health system but as the epidemic was expanding, the Health Regional Agencies (ARS) were given autonomy in terms of screening strategies implementation; however, at the same time, a strict lockdown approach was instituted for all regions.^{5,6} Among french regions, the main difference in their strategies was the intensity of testing policies. Screening policies and mortality rate might be related to the fact that testing allows authorities to detect and isolate infected people and to prevent them from transmitting the virus; and also enables early treatment, thus increasing the chances of cure.⁷

We propose a novel approach to assess the impact of focused screening strategies on mortality rates, which exploits policy discontinuities at region borders and contiguous department pairs that are located on opposite sides of a region border. This methodology has been used in an economic setting to evaluate the effects of the minimum wage on earnings and employment in the US.⁸

Figure 1: Cumulated number of deaths and tests.

Expressed as for 10000 populations. The cumulated number of deaths are those observed in hospitals. The cumulated number of tests are the RT-PCR tests made in private laboratories.

Materials and methods

Data sources and procedures

We conducted a retrospective study, with prospective database, including the total of patients who were admitted to hospital and afterwards discharged, the total of casualties and the total of test performed for screening COVID-19 infection (RT-PCR) out-of-hospital medical laboratories. The sample cover the period from 19/03/2020 to 17/04/2020, which corresponds to a lockdown period in France. All the information was provided daily by the [French Public Health Agency](#) (Santé Publique France). The data was gathered from different geographic areas within France and no other countries were included. The analysis takes place at the departmental level. We merged this dataset with information on hospital occupancy rates for intensive care units published by the [French Ministry of Health](#). Sociodemographic data were extracted from the [National Institute of Statistics and Economic Studies](#). Our analysis took place at the departmental level.

Fixed-effects model: Empirical strategy

In our study, we exploit the fact that from 14/03/2020, the French government has activated the third stage of the national plan for the prevention and control of the epidemic, which translates into non-systematic testing of symptomatic individuals. From this date, testing policies were determined at the region level by the Regional Public Health Agencies. We used a fixed-effects model to assess the impact of the number of tests performed over time at a local geographical level (department) on fatality-cases. In fixed-effects models, subjects serve as their own controls, providing a means for controlling omitted-variable bias. Otherwise stated, fixed-effects models allow controlling for time-invariant heterogeneity, i.e. all possible characteristics that do not change over time.⁹

We used two distinct samples: i) The all-department sample (AD sample) that includes 94 departments distributed across 12 regions; ii) The contiguous border department-pair sample (CBDP sample) that contains all the contiguous department pairs that straddle a region boundary. Metropolitan France counts 96 departments. We excluded two departments, Haute-Corse and Corse-du-Sud, that are part of a region, Corsica, that does not share any direct border with others. Among the 94 departments, 69 lie along a region border. As each department may belong to several department-pairs, we have a total of 237 distinct department-pairs. Our strategy consisted in comparing all contiguous department pairs sharing a region border (See Figure 3 for an example) to identify the effect of testing on the case fatality rate. Tests rate and death rates were calculated using the number of RT-PCR tests and the number of deaths related to COVID-19 divided by the number of patients admitted to the hospital, respectively.

A. Case fatality ratio - 17-04-2020

B. Test ratio - 17-04-2020

Figure 2: Tests rate and death rates across Region in France. Test rate: number of RT-PCR tests divided by the number of patients admitted to the hospital for COVID-19. Death rate: number of death in hospital due to COVID-19 divided by the number of patients admitted to the hospital. We use shapefiles for [Regions](#) and [Departments](#) to construct the maps and compute the contiguity matrix. Reading: PACA belongs to the top 20% of regions that test more and to the bottom 20% of regions that have the lowest fatality ratio.

Figure 3: Contiguous border department pairs Example with "Nouvelle Aquitaine" and "Occitanie" regions.

Fixed-effects model: Estimation strategy

Specifications using the all department sample (AD Sample)

We first estimate the effect of testing on case-fatality rate using the canonical fixed-effects model and the AD sample (Specification (1)):

$$CFR_{it} = \beta_1 TEST_{it} + \phi_i + u_{it} \quad (1)$$

where i denote the department, t the time, CFR_{it} is the case fatality rate in department i at time t , $TEST_{it}$ represents the percentage of people hospitalized that are tested in department i at time t , ϕ_i is a department fixed effect, and u_{it} an error term.

Specifications using the contiguous border department-pair sample (CBDP Sample)

We now turn to our preferred identification strategy, which exploits policy discontinuities at region borders. To achieve identification, we estimate the following model using the CBDP sample (Specification (4)):

$$CFR_{ipt} = \alpha + \beta_2 TEST_{it} + \mu_i + \nu_p + \epsilon_{ipt} \quad (2)$$

where i denote the department, p the department-pair, t the time, CFR_{ipt} is the case fatality rate in department i in department-pair p at date t , $TEST_{it}$ represents the percentage of people hospitalized that are tested in department i in department-pair p at date t , μ_i represents a department fixed effect and ν_p a department-pair fixed effect. Standard errors are clustered on the region and border segment separately to account for possible correlation in the residuals⁸.

Results

Study Sample

	All-department sample		Contiguous border department-pair sample	
	Mean	s.d.	Mean	s.d.
<i>Variables related to individual health</i>				
Number of people hospitalized	433.64	785.26	405.32	728.12
Number of tests	613.43	1293.99	572.43	1141.69
Number of positive tests	155.71	361.35	152.45	345.93
Number of patient cured	154.55	285.52	145.20	265.71
Number of deaths	53.71	113.22	49.58	102.51
<i>Variables related to health facilities</i>				
Number of hospital beds (resuscitation unit)	52.30	63.33	47.30	55.92
Number of hospital days (resuscitation unit)	16704	21270	15124	18655
Occupancy rate (resuscitation unit)	107.84	43.67	109.21	45.73
<i>Sociodemographic variables</i>				
Surface area (in km^2)	52057	22718	52183	22994
Population density	574.86	2453.53	500.79	2106.07
% of people aged 65 and over	21.16	3.78	21.18	3.93
Household size	2.18	0.12	2.19	0.13
Poverty rate	14.54	3.02	14.44	2.89
Number of periods	30	30	30	30
Number of departments	94	94	69	69
Number of department-pairs	NA	NA	237	237
Number of regions	12	12	12	12

Table 1: Descriptive statistics

Note: Sample means are reported for all departments in France and for all contiguous border department-pairs with a full balanced panel of observations.

Although fixed-effects models control for all characteristics which do not change over time, we report some time-invariant variables in Table 1 for information. The average number of tested individuals was 613.43 per department with

a share of positive cases of approximately 25 percent. We count a total of 40762 hospitalizations. The observed share of the population above age 65 was roughly 21 percent. As shown by Figure 1, the number of deaths increased quickly, from 154 on March 19th to 11532 on April 17. Over the same period, the number of tests increased from 1713 to 133108.

The path of mortality and testing was not homogenous over the territory. The autonomy given to Regional Public Health Agencies generated unprecedented differences in testing rate across regions and strong discontinuities at region borders (See Figure 2). Our strategy consists in comparing all contiguous department pairs sharing a region border (See Figure 3 for an example) to identify the effect of testing on the case fatality rate.

The department fixed effect captures time-invariant heterogeneity across departments. This includes sociodemographic variables (such as the structure of age, race, or gender in the population), but also many variables related to health facilities (number of hospitals, medical density or medical devices). We add time-varying confounding factors in specifications (b) and (c). Specification (b) includes the occupancy rate of the resuscitation units, while specification (c) also controls for the rate of positive tests. The first variable controls for the capacity of hospitals to treat patients at different stages of the COVID-19 epidemic while the second controls for selection bias. Table 2 reports the estimates provided by specifications (a)-(c). Our baseline estimates reveal that a 1 percentage point (pp) increase in the tests/hospitalizations ratio leads to a statistically significant decrease in the case mortality rate by slightly less than 0.001pp.

Specification	(a)	(b)	(c)
Test rate	-0.000849*** (0.000281)	-0.000878*** (0.000279)	-0.001009*** (0.000286)
Controls			
Occupancy rate (resuscitation unit)	NO	YES	YES
Rate of positive tests	NO	NO	YES
Number of periods	30	30	30
Number of departments	94	94	94
Number of regions	12	12	12

Table 2: Effect of tests on case fatality rate - All-department sample
Standard errors in parentheses. *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Finally, table 3 displays the results for specification (d)-(f). Our estimates reveal that a 1 pp increase in the tests/hospitalizations ratio leads to a statistically significant drop of case mortality rate by 0.001 pp. Putting these numbers into perspective involves that for each additional 1000 tests, one person would have remained alive.

Specification	(d)	(e)	(f)
Test rate	-0.001043** (0.000516)	-0.001069** (0.000508)	-0.001204** (0.000533)
Controls			
Occupancy rate (resuscitation unit)	NO	YES	YES
Rate of positive tests	NO	NO	YES
Department-pair $\times$ dummies	YES	YES	YES
Number of periods	30	30	30
Number of departments	69	69	69
Number of department-pairs	237	237	237
Number of regions	12	12	12

Table 3: Effect of tests on case fatality rate - Contiguous border department-pair sample
Standard errors in parentheses. *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Discussion

SARS-CoV-2 outbreak is one of the major public health emergencies of international concern for decades. Countries have implemented various measures mostly based on mobility restriction, social distancing, and regional or national lockdown. All of these public health measures are aimed at "flattening the curve" of the infected cases to limit avoidable mortality due to overburdened health care systems. We evaluate the effect of mass screening COVID-19 on mortality rate in France during the first month of the lockdown. We take advantage of the difference in screening intensity among French regions. We first estimate the effect of testing on case-fatality rate using the canonical fixed-effects model and the AD sample and find that the increase of screening rate of 1 pp allows mortality rate to decrease of nearly 0.001 pp. We confirm our results by estimating the fixed-effects model using the CBDP sample which compares contiguous French departments sharing region borders.

To the best of our knowledge, no large randomized controlled trial (RCT) has been implemented to investigate the effect of tests on the case-fatality rate,

probably due to time, budget, or ethical constraints. When RCT are difficult to implement or unethical, natural experiments (NE) are ones of the best alternative. The principle of NE is to mimic the existence of treatment and control groups using an instrumental variable that induces a change in the explanatory variable but has any direct effect on the outcome. However, in the case of the COVID-19 epidemics, finding a suitable instrument remains a hard task. In the absence of RCT or NE, many researchers try to approximate using standard methods such as linear regression, logistic regression, or propensity scores. However, such methods are subject to the well-known omitted-variable bias, leading to severe bias in estimating the effects of the variables that are included. Consequently, causal inference via statistical adjustment represents a poor alternative to randomized experiments. In such a context, panel data models represent the best way to control for heterogeneity and to improve causal estimation.^{8,9} We use a fixed-effects model because it represents a powerful tool for longitudinal data analysis.⁹ However, such a model requires substantial differences between treatment intensities across entities and time to get precise estimates. Our data meets these conditions: i) no region has the same test rate path than other regions over the period considered; ii) the test rate varies greatly across regions and time. Methods based on regional controls and policy discontinuities have several advantages: i) contiguous border departments are relatively similar, in particular with regard to health trends, which are of major importance in the context of an epidemic; ii) the testing policy is determined at the region level and is largely exogenous from the point of view of a department, which rules out potential reverse causality.⁸

Until a vaccine is developed, the only way to prevent an unrestrained scenario is to control the spread of SARS-CoV-2. This is a challenging task because some asymptomatic infected patients could potentially spread the virus. Literature report an alarming proportion of asymptomatic infected cases. Epidemiological data from the Diamond Princess cruise ship revealed only 18% of positive cases reported no symptoms.¹⁰ Two hospitals in New York implemented universal testing for SARS-CoV-2 with nasopharyngeal swabs in women who were admitted for delivery, and revealed that nearly 90% of patients who were positive for SARS-CoV-2 at admission reported no symptoms.¹¹ Overall population screening in Iceland revealed that only 57% of participants with positive tests reported symptoms of Covid-19.¹² This proportion could be even higher, because of false negative results of tests to detect SARS-CoV-2.¹³ Testing is part of a strategy to limit the transmission of the virus and WHO recommends a rapid diagnosis and isolation of cases in combination with a rigorous tracking and precautionary self-isolation of close contacts. Several authors support the implementation of mass screening policies.^{3,14} In our opinion, mass screening may positively impact the fatality case rate in differ-

ent ways. First, unfocused testing, i.e. not limited to symptomatic subjects, could improve the monitoring of the progress of the epidemic and facilitate decision-making by the health authorities. The use of "case definition", given the limited knowledge of the new disease, probably resulted in a low sensitivity to detect infected subjects, resulting in a delayed perception of the progression of the epidemic^{15;16}. Screening strategies are subject to the availability of tests which indirectly shapes epidemic curves.¹⁷ While the USA increased their screening capacities between late-February to early-March, the country experienced a rapid increase of total infected cases. ("CDC - Testing in the U.s." n.d.) Second, mass screening may also allow early identification of infected subjects and rapid implementation of isolation measures. Early reports from Wuhan suggest that public health interventions combining universal symptoms survey, traffic restriction and home quarantine resulted were temporarily associated with an increased control of the outbreak.^{10;18} A modeling from Singapore suggests that quarantining of infected individuals and their family members, school closure and workplace distancing could reduce the progression of the epidemic but is associated to a significant economic cost.¹⁹ Review from the Cochrane database concludes that quarantine is important in reducing the number of covid-19 cases but is dependent on screening strategies.²⁰ Also, a US survey on the impact of school closure on mortality reports that the transmission prevention by school closure needs to be weighted with the potential loss of health-care workers.²¹ This supports that public health decisions should be as focused as possible in order to limit the negative impact on the economy and the society²². Importance of rapid diagnosis and case identification and isolation will become of utmost importance with the end of lockdowns.

Our study far supports a significant impact of screening strategies on the case-fatality rate in France. Notwithstanding, there are some limitations to our results. First, they belong to France and it would be very hazardous to pretend that they apply to other countries because their exposition to the COVID-19 is different, they adopted different strategies, and have different health structures. Second, to provide further evidence on this relation, it would be worth applying this methodology to other countries for which such data are available and in which testing policies are sufficiently heterogeneous across geographical areas.

In addition, the data on tests collected by the French Public Health Agency are those made by private laboratories and do not include those made in public hospitals. This represents an important share of tests (between half and two thirds) and we cannot rule out the possibility that this unobservable amount of screening activity may affect our results. Lastly, our study cannot quantify the respective contribution of the treatment delivered to screened and infected

individuals or the lower dissemination of the virus that results from quarantining policies.

Conclusion

COVID-19 intensive screening policies were significantly associated with a decrease in the fatality-case rate in France. These results support the implementation of mass screening strategies and could provide important information for decision-makers in the fight against SARS-CoV2 pandemic. The optimal testing strategy might also concern economic issues. Indeed, the Bank of France estimated that each fortnight of lockdown costs to France 1.5% of annual GDP (nearly USD48 billions).^{23;24} The surge in government expenditures and the lower revenues from tax collection that result from the sharp decline in economic activity may also be detrimental for the government budget. From a costs/benefits perspective one might naturally wonder what is the optimal policy capable of containing the outbreak and lowering the fatality rate. This is in our research agenda.

References

- [1] WHO COVID-19 dashboard;. Accessed: 2020-04-21. <https://covid19.who.int/>.
- [2] WHO-19 announces COVID-19 outbreak a pandemic;. Accessed: 2020-04-21. <http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>.
- [3] Peto J. Covid-19 mass testing facilities could end the epidemic rapidly. *Bmj*. 2020;368.
- [4] Tanne JH, Hayasaki E, Zastrow M, Pulla P, Smith P, Rada AG. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. *Bmj*. 2020;368.
- [5] Chevreul K, Durand-Zaleski I, Bahrami S, Hernández-Quevedo C, Mladovsky P, et al. France: Health system review. 2010;.
- [6] French Prime Minister;. Accessed: 2020-04-21. https://www.gouvernement.fr/sites/default/files/risques/pdf/plan_pandemie_grippale_2011.pdf.
- [7] Ruan S. Likelihood of survival of coronavirus disease 2019. *The Lancet Infectious Diseases*. 2020;.
- [8] Dube A, Lester TW, Reich M. Minimum wage effects across state borders: Estimates using contiguous counties. *The Review of Economics and Statistics*. 2010;92(4):945–964.
- [9] Gunasekara FI, Richardson K, Carter K, Blakely T. Fixed effects analysis of repeated measures data. *International journal of epidemiology*. 2014;43(1):264–269.
- [10] Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. *JAMA*. 2020;.
- [11] Sutton D, Fuchs K, D’Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. *New England Journal of Medicine*. 2020;.
- [12] Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. *New England Journal of Medicine*. 0;0(0):null.

- [13] Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology*. 2020;p. 200642.
- [14] Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. *Swiss medical weekly*. 2020;150(1112).
- [15] Tsang TK, Wu P, Lin YLY, Lau E, Leung GM, Cowling BJ. Impact of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China. *medRxiv*. 2020;.
- [16] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama*. 2020;.
- [17] Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19-studies needed. *New England Journal of Medicine*. 2020;.
- [18] Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health*. 2020;.
- [19] Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. *The Lancet Infectious Diseases*. 2020;.
- [20] Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane Database of Systematic Reviews*. 2020;(4).
- [21] Bayham J, Fenichel EP. Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modelling study. *The Lancet Public Health*. 2020;.
- [22] Appleby J. Tackling covid-19: are the costs worth the benefits? *BMJ*. 2020;369. Available from: <https://www.bmj.com/content/369/bmj.m1496>.
- [23] Bank of France - Macroeconomic projections France;. Accessed: 2020-04-25. https://www.banque-france.fr/sites/default/files/media/2020/04/14/update_on_business_conditions_in_france_at_the_end_of_march_2020.pdf.

[24] OECD data;. Accessed: 2020-04-25. <https://data.oecd.org/gdp/gross-domestic-product-gdp.htm>.